Outstanding regulatory aspects in the European pharmaceutical market.
- Published in:
- 1999
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 1999 AND VI 15 AND IP 6
Results: 10
1
2
A Review of Quality of Life in Alzheimer’s Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects.
- Published in:
- PharmacoEconomics, 1999, v. 15, n. 6, p. 641, doi. 10.2165/00019053-199915060-00010
- By:
- Publication type:
- Article
3
Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
- Published in:
- 1999
- By:
- Publication type:
- journal article
4
Standard Cost Lists for Healthcare in Canada: Issues in Validity and Inter-Provincial Consolidation.
- Published in:
- PharmacoEconomics, 1999, v. 15, n. 6, p. 551, doi. 10.2165/00019053-199915060-00003
- By:
- Publication type:
- Article
5
Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference?
- Published in:
- 1999
- By:
- Publication type:
- journal article
6
Costs of diabetes. A methodological analysis of the literature.
- Published in:
- 1999
- By:
- Publication type:
- journal article
7
Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.
- Published in:
- 1999
- By:
- Publication type:
- journal article
8
Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
- Published in:
- 1999
- By:
- Publication type:
- journal article
9
A review of quality of life in Alzheimer's disease. Parts 1 and 2: Issues in assessing disease impact and drug effects.
- Published in:
- 1999
- By:
- Publication type:
- commentary
10
A model to compute the medical cost of patients in intensive care.
- Published in:
- 1999
- By:
- Publication type:
- journal article